{{위키데이터 속성 추적}}
{{Infobox drug
| Verifiedfields = changed
| verifiedrevid = 477241856
| type = mab
| image = 

<!-- Monoclonal antibody data -->
| mab_type = mab
| source = u
| target = [[종양괴사인자 알파]]

<!-- Clinical data -->
| pronounce =
| tradename = Humira
| biosimilars = adalimumab-aacf,<ref name="Idacio EPAR">{{웹 인용| title=Idacio EPAR | website=[[European Medicines Agency]] (EMA) | date=29 January 2019 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/idacio | access-date=18 February 2020 | archive-date=30 December 2019 | archive-url=https://web.archive.org/web/20191230161513/https://www.ema.europa.eu/en/medicines/human/EPAR/idacio | url-status=live }}</ref> adalimumab-adaz,<ref name="Hyrimoz FDA label">{{웹 인용| title=Hyrimoz: FDA-Approved Drugs | website=U.S. [[Food and Drug Administration]] (FDA) | date=30 October 2018 | url=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761071 | archive-url=https://web.archive.org/web/20191207062533/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761071 | archive-date=7 December 2019 | url-status=live | access-date=6 December 2019}} {{PD-notice}}</ref> adalimumab-adbm,<ref name="Cyltezo FDA label">{{웹 인용|url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761058Orig1s014lbl.pdf |title=Archived copy |access-date=11 February 2023 |archive-date=8 November 2022 |archive-url=https://web.archive.org/web/20221108225856/https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761058Orig1s014lbl.pdf |url-status=live }}</ref> adalimumab-afzb,<ref name="Abrilada FDA label">{{웹 인용|url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761118s000lbl.pdf |title=Archived copy |access-date=11 February 2023 |archive-date=1 December 2022 |archive-url=https://web.archive.org/web/20221201004131/https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761118s000lbl.pdf |url-status=live }}</ref> adalimumab-aqvh,<ref name="Yusimry FDA label">{{웹 인용|url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761216s000lbl.pdf |title=Archived copy |access-date=11 February 2023 |archive-date=4 January 2023 |archive-url=https://web.archive.org/web/20230104091219/https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761216s000lbl.pdf |url-status=live }}</ref> adalimumab-atto,<ref name="Amjevita FDA label">{{웹 인용|url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761024s010lbl.pdf |title=Archived copy |access-date=11 February 2023 |archive-date=4 January 2023 |archive-url=https://web.archive.org/web/20230104090915/https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761024s010lbl.pdf |url-status=live }}</ref> adalimumab-bwwd,<ref name="Hadlima FDA label">{{웹 인용|url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761059s000lbl.pdf |title=Archived copy |access-date=11 February 2023 |archive-date=6 December 2022 |archive-url=https://web.archive.org/web/20221206075321/https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761059s000lbl.pdf |url-status=live }}</ref> adalimumab-fkjp,<ref name="Hulio FDA label">{{웹 인용|url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761154s000lbl.pdf |title=Archived copy |access-date=11 February 2023 |archive-date=6 December 2022 |archive-url=https://web.archive.org/web/20221206080221/https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761154s000lbl.pdf |url-status=live }}</ref> Abrilada,<ref name="Abrilada SBD">{{웹 인용| title=Summary Basis of Decision (SBD) for Abrilada | website=Health Canada | date=23 October 2014 | url=https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?linkID=SBD00552&lang=en | access-date=29 May 2022 | archive-date=29 May 2022 | archive-url=https://web.archive.org/web/20220529224341/https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?linkID=SBD00552&lang=en | url-status=live }}</ref> Amgevita,<ref name="Amgevita EPAR">{{웹 인용| title=Amgevita EPAR | website=[[European Medicines Agency]] (EMA) | date=17 September 2018 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/amgevita | access-date=18 February 2020 | archive-date=30 December 2019 | archive-url=https://web.archive.org/web/20191230161340/https://www.ema.europa.eu/en/medicines/human/EPAR/amgevita | url-status=live }}</ref> Amsparity,<ref name="Amsparity EPAR">{{웹 인용| title=Amsparity EPAR | website=[[European Medicines Agency]] (EMA) | date=9 December 2019 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/amsparity | access-date=18 February 2020 | archive-date=18 February 2020 | archive-url=https://web.archive.org/web/20200218190500/https://www.ema.europa.eu/en/medicines/human/EPAR/amsparity | url-status=live }}</ref> Ardalicip,<ref name="Ciptunec/Ardalicip APMDS" /> Cadalimab,<ref name="Cadalimab PR">{{보도자료 인용| title=Cadila Pharmaceuticals launches Cadalimab (Adalimumab biosimilar) for India | website=Cadila Pharmaceuticals | date=28 August 2020 | url=https://www.cadilapharma.com/news-release/cadila-pharmaceuticals-cadalimab-adalimumab/ | access-date=11 February 2023 | archive-date=30 November 2022 | archive-url=https://web.archive.org/web/20221130141016/https://www.cadilapharma.com/news-release/cadila-pharmaceuticals-cadalimab-adalimumab/ | url-status=live }}</ref> Ciptunec,<ref name="Ciptunec/Ardalicip APMDS" /> Cyltezo,<ref name="Cyltezo EPAR">{{웹 인용| title=Cyltezo EPAR | website=[[European Medicines Agency]] (EMA) | date=17 September 2018 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/cyltezo | access-date=18 February 2020 | archive-date=6 August 2020 | archive-url=https://web.archive.org/web/20200806180247/https://www.ema.europa.eu/en/medicines/human/EPAR/cyltezo | url-status=live }}</ref> Exemptia, Hadlima, Halimatoz,<ref name="Halimatoz EPAR">{{웹 인용| title=Halimatoz EPAR | website=[[European Medicines Agency]] (EMA) | date=17 September 2018 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/halimatoz | access-date=18 February 2020 | archive-date=30 December 2019 | archive-url=https://web.archive.org/web/20191230161739/https://www.ema.europa.eu/en/medicines/human/EPAR/halimatoz | url-status=live }}</ref> Hefiya,<ref name="Hefiya EPAR">{{웹 인용| title=Hefiya EPAR | website=[[European Medicines Agency]] (EMA) | date=17 September 2018 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/hefiya | access-date=18 February 2020 | archive-date=15 October 2019 | archive-url=https://web.archive.org/web/20191015195616/https://www.ema.europa.eu/en/medicines/human/EPAR/hefiya | url-status=live }}</ref> Hukyndra,<ref name="Hukyndra EPAR">{{웹 인용| title=Hukyndra EPAR | website=[[European Medicines Agency]] (EMA) | date=14 September 2021 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/hukyndra | access-date=23 April 2022 | archive-date=24 April 2022 | archive-url=https://web.archive.org/web/20220424041728/https://www.ema.europa.eu/en/medicines/human/EPAR/hukyndra | url-status=live }}</ref> Hulio,<ref name="Hulio EPAR">{{웹 인용| title=Hulio EPAR | website=[[European Medicines Agency]] (EMA) | date=17 September 2018 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/hulio | access-date=18 February 2020 | archive-date=24 March 2020 | archive-url=https://web.archive.org/web/20200324055630/https://www.ema.europa.eu/en/medicines/human/EPAR/hulio | url-status=live }}</ref> Hyrimoz,<ref name="Hyrimoz EPAR">{{웹 인용| title=Hyrimoz EPAR | website=[[European Medicines Agency]] (EMA) | date=17 September 2018 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/hyrimoz | access-date=18 February 2020 | archive-date=16 November 2019 | archive-url=https://web.archive.org/web/20191116205930/https://www.ema.europa.eu/en/medicines/human/EPAR/hyrimoz | url-status=live }}</ref> Idacio,<ref name="Idacio EPAR">{{웹 인용| title=Idacio EPAR | website=[[European Medicines Agency]] (EMA) | date=29 January 2019 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/idacio | access-date=18 February 2020 | archive-date=30 December 2019 | archive-url=https://web.archive.org/web/20191230161513/https://www.ema.europa.eu/en/medicines/human/EPAR/idacio | url-status=live }}</ref> Imraldi,<ref name="Imraldi EPAR">{{웹 인용| title=Imraldi EPAR | website=[[European Medicines Agency]] (EMA) | date=17 September 2018 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/imraldi | access-date=18 February 2020 | archive-date=24 March 2020 | archive-url=https://web.archive.org/web/20200324045318/https://www.ema.europa.eu/en/medicines/human/EPAR/imraldi | url-status=live }}</ref> Kromeya,<ref name="Kromeya EPAR">{{웹 인용| title=Kromeya EPAR | website=[[European Medicines Agency]] (EMA) | date=29 January 2019 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/kromeya | access-date=18 February 2020 | archive-date=30 December 2019 | archive-url=https://web.archive.org/web/20191230161654/https://www.ema.europa.eu/en/medicines/human/EPAR/kromeya | url-status=live }}</ref> Libmyris,<ref name="Libmyris EPAR">{{웹 인용| title=Libmyris EPAR | website=[[European Medicines Agency]] (EMA) | date=14 September 2021 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/libmyris | access-date=23 April 2022 | archive-date=24 April 2022 | archive-url=https://web.archive.org/web/20220424041731/https://www.ema.europa.eu/en/medicines/human/EPAR/libmyris | url-status=live }}</ref> Mabura, Simlandi,<ref name="Simlandi SBD">{{웹 인용| title=Summary Basis of Decision (SBD) for Simlandi | website=Health Canada | date=23 October 2014 | url=https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?linkID=SBD00585&lang=en | access-date=29 May 2022 | archive-date=29 May 2022 | archive-url=https://web.archive.org/web/20220529191115/https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?linkID=SBD00585&lang=en | url-status=live }}</ref> Solymbic,<ref name="Solymbic EPAR">{{웹 인용| title=Solymbic EPAR | website=[[European Medicines Agency]] (EMA) | date=17 September 2018 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/solymbic | access-date=18 February 2020 | archive-date=25 June 2019 | archive-url=https://web.archive.org/web/20190625133941/https://www.ema.europa.eu/en/medicines/human/EPAR/solymbic | url-status=live }}</ref> Trudexa,<ref>{{웹 인용| title=Trudexa EPAR | website=[[European Medicines Agency]] (EMA) | date=17 September 2018 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/trudexa | access-date=27 August 2021 | archive-date=18 February 2020 | archive-url=https://web.archive.org/web/20200218190523/https://www.ema.europa.eu/en/medicines/human/EPAR/trudexa | url-status=live }}</ref> Yuflyma,<ref name="Yuflyma EPAR">{{웹 인용| title=Yuflyma EPAR | website=[[European Medicines Agency]] (EMA) | date=9 December 2020 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/yuflyma | access-date=27 February 2021 | archive-date=28 August 2021 | archive-url=https://web.archive.org/web/20210828065111/https://www.ema.europa.eu/en/medicines/human/EPAR/yuflyma | url-status=live }}</ref> Yusimry<ref name="Yusimry FDA label" />
| Drugs.com = {{drugs.com|monograph|adalimumab}}
| MedlinePlus = a603010
| licence_CA = <!-- Health Canada may use generic or brand name (generic name preferred) -->
| licence_EU = yes
| DailyMedID = Adalimumab
| licence_US = <!-- FDA may use generic or brand name (generic name preferred) -->
| pregnancy_AU = C<ref name="Drugs.com pregnancy">{{웹 인용|title=Adalimumab Pregnancy and Breastfeeding Warnings |url=https://www.drugs.com/pregnancy/adalimumab.html |website=Drugs.com |access-date=19 March 2019 |archive-date=17 April 2021 |archive-url=https://web.archive.org/web/20210417111753/https://www.drugs.com/pregnancy/adalimumab.html |url-status=live }}</ref><ref name="Yuflyma APMDS" /><ref name="Ciptunec/Ardalicip APMDS" />
| pregnancy_category= 
| routes_of_administration = [[피하 주사]]
| class = [[TNF 억제제]]
| ATCvet = 
| ATC_prefix = L04
| ATC_suffix = AB04
| ATC_supplemental = 

<!-- Legal status -->
| legal_AU = S4<ref name="Yuflyma APMDS">{{웹 인용| title=Yuflyma APMDS | website=Therapeutic Goods Administration (TGA) | date=8 April 2022 | url=https://www.tga.gov.au/resources/auspmd/yuflyma | access-date=24 April 2022 | archive-date=24 April 2022 | archive-url=https://web.archive.org/web/20220424055641/https://www.tga.gov.au/apm-summary/yuflyma | url-status=live }}</ref><ref name="Ciptunec/Ardalicip APMDS">{{웹 인용| title=Ciptunec/Ardalicip APMDS | website=Therapeutic Goods Administration (TGA) | date=27 September 2022 | url=https://www.tga.gov.au/resources/auspmd/ciptunecardalicip | access-date=29 September 2022 }}</ref>
| legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F-->
| legal_BR_comment =
| legal_CA = Rx-only
| legal_CA_comment = /&nbsp;Schedule D
| legal_DE = <!-- Anlage I, II, III or Unscheduled-->
| legal_DE_comment = 
| legal_NZ = <!-- Class A, B, C -->
| legal_NZ_comment = 
| legal_UK = POM<ref name="Humira SmPC">{{웹 인용| title=Humira 40 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC) | website=(emc) | date=27 November 2019 | url=https://www.medicines.org.uk/emc/product/2150/smpc | access-date=12 August 2020 | archive-date=4 August 2020 | archive-url=https://web.archive.org/web/20200804205216/https://www.medicines.org.uk/emc/product/2150/smpc | url-status=live }}</ref>
| legal_US = Rx-only<ref name="Humira FDA label">{{웹 인용| title=Humira- adalimumab kit Humira- adalimumab injection, solution | website=DailyMed | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=608d4f0d-b19f-46d3-749a-7159aa5f933d#section-1 | access-date=18 February 2020 | archive-date=21 June 2020 | archive-url=https://web.archive.org/web/20200621160349/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=608d4f0d-b19f-46d3-749a-7159aa5f933d#section-1 | url-status=live }}</ref><ref name="Hyrimoz FDA label" /><ref name="Idacio FDA label">{{웹 인용|url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761255Orig1s000TOC.cfm |title=Drug Approval Package: Idacio |publisher=U.S. [[Food and Drug Administration]] (FDA) |access-date=9 February 2023 |date=9 February 2023 |archive-date=10 February 2023 |archive-url=https://web.archive.org/web/20230210001159/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761255Orig1s000TOC.cfm |url-status=live }}</ref><ref name="Abrilada FDA label" /><ref name="Yusimry FDA label" /><ref name="Hadlima FDA label" /><ref name="Hulio FDA label" />
| legal_EU = Rx-only<ref name="Humira EPAR" />
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV-->
| legal_UN_comment = 
| legal_status = <!--For countries not listed above-->

<!-- Pharmacokinetic data -->
| bioavailability = 64% ([[피하 투여|피하]]), 0% ([[경구 투여|경구]])
| protein_bound = 
| metabolism = 
| metabolites = 
| onset = 
| elimination_half-life = 10~20일
| duration_of_action =
| excretion =

<!-- Identifiers -->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 331731-18-1
| CAS_supplemental = 
| PubChem = 
| PubChemSubstance = 
| IUPHAR_ligand = 
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00051
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = FYS6T7F842
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02597
| ChEBI = 
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1201580
| NIAID_ChemDB =
| PDB_ligand = 
| synonyms = D2E7

<!-- Chemical and physical data -->
| IUPAC_name = 
| C=6428 | H=9912 | N=1694 | O=1987 | S=46
| SMILES = 
| StdInChI = 
| StdInChI_comment = 
| StdInChIKey = 
| density = 
| density_notes = 
| melting_point = 
| melting_high = 
| melting_notes = 
| boiling_point = 
| boiling_notes = 
| solubility = 
| sol_units = 
| specific_rotation = 
}}

<!-- 정의와 의학적 사용 -->
'''아달리무맙'''(adalimumab)은 [[류마티스 관절염]], [[건선성 관절염]], [[강직성 척추염]], [[크론병]], [[궤양성 대장염]], [[판상건선]], [[화농성 한선염]], [[포도막염]], [[소아 특발성 관절염]] 등의 치료에 이용되는 [[단클론 항체]]이다.<ref name=AHFS2019/><ref name=BNF76>{{서적 인용|title=British national formulary: BNF 76 |title-link=British National Formulary |date=2018 |publisher=Pharmaceutical Press|isbn=9780857113382|pages=1074|edition=76}}</ref><ref name="hidradenitis suppurativa">{{웹 인용|title=FDA Clears Adalimumab (Humira) for Hidradenitis Suppurativa |first=Megan |last=Brooks |url=https://www.medscape.com/viewarticle/850897|date=11 September 2015|access-date=13 October 2017|publisher=Medscape|archive-date=21 January 2021|archive-url=https://web.archive.org/web/20210121031028/https://www.medscape.com/viewarticle/850897|url-status=live}}</ref> [[피하 주사]]로 투여한다.<ref name=AHFS2019>{{웹 인용|title=Adalimumab Monograph for Professionals |url=https://www.drugs.com/monograph/adalimumab.html |website=Drugs.com |publisher=American Society of Health-System Pharmacists |date=14 May 2018 |access-date=18 March 2019 |archive-date=21 November 2020 |archive-url=https://web.archive.org/web/20201121141501/https://www.drugs.com/monograph/adalimumab.html |url-status=live }}</ref> '''휴미라'''(Humira) 등의 상품명으로 판매된다.

<!-- 부작용과 작용 기전 -->
아달리무맙은 [[항류마티스제]](DMARD)이며 [[종양괴사인자 알파]](TNFα)를 억제하여 작용하는 [[TNF 억제제]]의 일종이다.<ref name=AHFS2019/> 흔한 부작용에는 [[상기도 감염]], 주사 부위의 통증, [[발진 (의학)|발진]], [[두통]]이 있다.<ref name=AHFS2019/> 다른 비교적 드문 부작용에는 중증 감염, [[암]], [[아나필락시스]], [[B형 간염]]의 재활성화, [[다발성 경화증]], [[심부전]], [[간부전]], [[재생불량성 빈혈]] 등이 있다.<ref name=AHFS2019/> [[임신]] 중 사용은 권고되지 않으나, 일부 문헌에서는 [[모유 수유|수유]] 중 사용은 안전하다고 기술하고 있다.<ref name="Drugs.com pregnancy" /><ref name="BNF76" />

아달리무맙은 2002년 처음으로 미국에서 사용을 승인 받았다.<ref name=AHFS2019/><ref name="FDA approval">{{웹 인용| title=Drug Approval Package: Humira (adalimumab) | website=U.S. [[Food and Drug Administration]] (FDA) | date=7 April 2017 | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/125057_toc.cfm | access-date=18 February 2020 | archive-date=18 February 2020 | archive-url=https://web.archive.org/web/20200218175026/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/125057_toc.cfm | url-status=live }}</ref> 현재는 [[WHO 필수 의약품 목록]]에 수록되어 있다.<ref name="WHO21st">{{서적 인용| vauthors = ((World Health Organization)) | title = World Health Organization model list of essential medicines: 21st list 2019 | year = 2019 | hdl = 10665/325771 | author-link = World Health Organization | publisher = World Health Organization | location = Geneva | id = WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO | hdl-access=free }}</ref><ref name="WHO22nd">{{서적 인용| vauthors = ((World Health Organization)) | title = World Health Organization model list of essential medicines: 22nd list (2021) | year = 2021 | hdl = 10665/345533 | author-link = World Health Organization | publisher = World Health Organization | location = Geneva | id = WHO/MHP/HPS/EML/2021.02 | hdl-access=free }}</ref> 여러 가지 [[바이오시밀러]] 약제로도 이용 가능하다.<ref name="pmid31322440">{{저널 인용| vauthors = Peyrin-Biroulet L, Danese S, Cummings F, Atreya R, Greveson K, Pieper B, Kang T | display-authors = 6 | title = Anti-TNF biosimilars in Crohn's Disease: a patient-centric interdisciplinary approach | journal = Expert Review of Gastroenterology & Hepatology | volume = 13 | issue = 8 | date = 26 July 2019 | issn = 1747-4124 | doi = 10.1080/17474124.2019.1645595 | pages = 731–738 | pmid = 31322440 | doi-access = free }}</ref> 2020년 기준으로는 미국에서 200만 건 넘게 처방되어 가장 많이 처방된 약제 205위에 들었다.<ref>{{웹 인용| title = The Top 300 of 2020 | url = https://clincalc.com/DrugStats/Top300Drugs.aspx | website = ClinCalc | access-date = 7 October 2022 | archive-date = 12 February 2021 | archive-url = https://web.archive.org/web/20210212142534/https://clincalc.com/DrugStats/Top300Drugs.aspx | url-status = live }}</ref><ref>{{웹 인용| title = Adalimumab - Drug Usage Statistics | website = ClinCalc | url = https://clincalc.com/DrugStats/Drugs/Adalimumab | access-date = 7 October 2022 | archive-date = 8 July 2020 | archive-url = https://web.archive.org/web/20200708061547/https://clincalc.com/DrugStats/Drugs/Adalimumab | url-status = live }}</ref>

== 의학적 사용 ==
미국에서 아달리무맙의 [[적응증]]은 류마티스 관절염, 소아 특발성 관절염, 건선성 관절염, 강직성 척추염, 성인의 크론병, 소아의 크론병, 궤양성 대장염, 판상건선, 화농성 한선염, 포도막염으로 제시되어 있다.<ref name="Humira FDA label" /><ref name="Imraldi label">{{웹 인용| title=Imraldi- adalimumab injection, solution | website=DailyMed | date=23 January 2018 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=acdfaa71-27ed-4717-8e7d-f1a5fe0d1fa6 | access-date=18 February 2020 | archive-date=21 September 2020 | archive-url=https://web.archive.org/web/20200921060811/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=acdfaa71-27ed-4717-8e7d-f1a5fe0d1fa6 | url-status=live }}</ref>

[[유럽 연합|EU]]에서의 적응증은 다음과 같다.<ref name="Humira EPAR">{{웹 인용| title=Humira EPAR | website=[[European Medicines Agency]] (EMA) | date=17 September 2018 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/humira | access-date=18 February 2020 | archive-date=18 February 2020 | archive-url=https://web.archive.org/web/20200218190451/https://www.ema.europa.eu/en/medicines/human/EPAR/humira | url-status=live }} Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.</ref>
* 판상건선 - 피부에 빨갛고 비늘 같은 병변이 생기는 질환
* 건선성 관절염 - 피부에 빨갛고 비늘 같은 병변이 생기며, [[관절염]]을 동반하는 질환
* 류마티스 관절염 - 관절에 염증을 일으키는 류마티스성 질환
* [[축성 척추관절염]] - 척추의 염증으로 인해 [[요통]]을 유발하는 질환. 강직성 척추염을 포함한다. 또한 X선 영상에서 질환이 보이지 않아도 명확한 염증 소견이 있을 시에도 처방할 수 있다.
* 다발성 소아 특발성 관절염과 활성 건염 관련 관절염( active enthesitis-related arthritis) - 두 질환 모두 관절에 염증을 일으키는 드문 질환이다.
* 크론병 - 창자에 염증을 일으키는 질환
* 궤양성 대장염 - 창자를 둘러싸는 [[위장관벽|벽]]에 염증과 궤양을 일으키는 질환
* 화농성 한선염 - 장기간에 걸쳐 발생하는 피부 질환으로 피부에 종기와 흉터가 난다.
* 비감염성 포도막염 - 안구의 흰자 아래층에 감염 이외의 원인으로 인해 발생하는 염증
* 공격적이며 진행성인 폐와 뼈의 만성 [[유육종증]]

=== 류마티스 관절염 ===
아달리무맙은 중등도에서 중증의 성인 [[류마티스 관절염]]에 사용하여 증상을 줄일 수 있다고 밝혀져 있다. 단독으로 쓰거나 다른 [[항류마티스제]]와 병용할 수 있다.<ref>{{저널 인용|vauthors=Navarro-Sarabia F, Ariza-Ariza R, Hernandez-Cruz B, Villanueva I |title=Adalimumab for treating rheumatoid arthritis. |journal=The Cochrane Database of Systematic Reviews |date=20 July 2005 |issue=3 |pages=CD005113 |doi=10.1002/14651858.CD005113.pub2 |pmid=16034967 |doi-access=free }}</ref> 또한 4세 이상의 소아에서, 중등도에서 중증의 [[소아 특발성 관절염]]에도 효과가 있으며 치료용 약제로 권장된다. 2002년 이후 미국의 경우, 류마티스 관절염에서는 단독으로 쓰거나 [[메토트렉세이트]] 등의 약제와 병용하도록 권고된다.<ref>{{웹 인용|first=Jay P. |last=Siegel |website=U.S. [[Food and Drug Administration]] (FDA) |title=Product Approval Information - Licensing Action |access-date=4 February 2014 |url=https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/adalabb123102L.htm |date=31 December 2002 |name-list-style=vanc |archive-date=24 October 2020 |archive-url=https://web.archive.org/web/20201024195343/https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/adalabb123102L.htm |url-status=live }} {{PD-notice}}</ref> 효과는 메토트렉세이트와 비슷하고, 아달리무맙과 메토트렉세이트를 함께 썼을 때 메토트렉세이트 단독으로 사용했을 때보다 반응률이 두 배 가까이 올라간다.<ref name="AAFP">{{저널 인용|last=Welch |first=Beth |title=Adalimumab (Humira) for the Treatment of Rheumatoid Arthritis |journal=American Family Physician |volume=78 |issue=12 |date=15 December 2008 |issn=0002-838X |url=http://www.aafp.org/afp/2008/1215/p1406.html |access-date=9 September 2019 |pages=1406–1408 |name-list-style=vanc |archive-date=24 November 2020 |archive-url=https://web.archive.org/web/20201124103428/https://www.aafp.org/afp/2008/1215/p1406.html |url-status=live }}</ref>

=== 강직성 척추염 ===
아달리무맙은 성인의 [[강직성 척추염]]의 증상을 완화시킬 수 있으며, 치료용 약제로 승인되어 있다.<ref>{{저널 인용|vauthors=Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras MM, Tanjong Ghogomu E, Benkhalti Jandu M, Tugwell P, Wells GA|display-authors=6|title=TNF-alpha inhibitors for ankylosing spondylitis.|journal=The Cochrane Database of Systematic Reviews|date=18 April 2015|volume=4|issue=4|pages=CD005468|pmid=25887212|doi=10.1002/14651858.CD005468.pub2|url=http://ecite.utas.edu.au/120128|access-date=14 December 2019|archive-date=20 September 2020|archive-url=https://web.archive.org/web/20200920134452/http://ecite.utas.edu.au/120128|url-status=live}}</ref>

=== 크론병 ===
아달리무맙은 중등도에서 중증 [[크론병]]의 증상을 줄여줄 수 있다.<ref name="pmid31322440" /><ref name="Podolsky">{{저널 인용|vauthors=Podolsky DK|date=August 2002|title=Inflammatory bowel disease|journal=N Engl J Med|volume=347|issue=6|pages=417–29|doi=10.1056/NEJMra020831|pmid=12167685|url=https://gut.bmj.com/content/gutjnl/39/Suppl_1/A15.full.pdf|access-date=24 September 2019|archive-date=14 March 2020|archive-url=https://web.archive.org/web/20200314042731/https://gut.bmj.com/content/gutjnl/39/Suppl_1/A15.full.pdf|url-status=live}}</ref><ref>{{저널 인용| vauthors = Gearry RB, Frampton C, Inns S, Poppelwell D, Rademaker M, Suppiah R | title=VITALITY: impact of adalimumab on health and disability outcomes in patients with Crohn's disease, rheumatoid arthritis, or psoriasis treated in clinical practice in New Zealand | journal=Current Medical Research and Opinion | volume=35 | issue=10 | date=3 July 2019 | issn=0300-7995 | doi=10.1080/03007995.2019.1634952 | pages=1837–1846 | pmid = 31233347| s2cid=195354397 }}</ref> 영국에서는 2009년부터 해당 적응증으로 사용이 승인되었다.<ref>{{웹 인용| last = Morey | first = Sheralyn | title = UK – Summary of NICE Approvals in September 2009 | date = 17 September 2009 | access-date = 4 February 2014 | url = https://worldpharmaoutlook.blogspot.com/2009/09/uk-summary-of-nice-approvals-in.html | name-list-style = vanc | archive-date = 20 September 2018 | archive-url = https://web.archive.org/web/20180920115308/http://worldpharmaoutlook.blogspot.com/2009/09/uk-summary-of-nice-approvals-in.html | url-status = live }}</ref>

=== 궤양성 대장염 ===
아달리무맙은 [[궤양성 대장염]]에서 효과적이며 잘 듣는다고 알려져 있다. [[미국 식품의약국]](FDA)에서 성인의 중등도에서 중증 궤양성 대장염 치료용으로 승인되어 있다.<ref>{{보도자료 인용|url=https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm321650.htm |title=FDA approves Humira to treat ulcerative colitis |date=28 September 2012 |publisher=U.S. [[Food and Drug Administration]] (FDA) | archive-url=https://web.archive.org/web/20120930235859/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm321650.htm |archive-date=30 September 2012| url-status=dead }} {{PD-notice}}</ref><ref>{{보도자료 인용| title=Abbott's Humira (adalimumab) Receives U.S. FDA Approval for the Treatment of Adult Patients with Moderate to Severe Ulcerative Colitis | website=Abbott | date=28 September 2012 | url=https://abbott.mediaroom.com/2012-09-28-Abbotts-HUMIRA-adalimumab-Receives-U-S-FDA-Approval-for-the-Treatment-of-Adult-Patients-with-Moderate-to-Severe-Ulcerative-Colitis | archive-url=https://web.archive.org/web/20191119023917/https://abbott.mediaroom.com/2012-09-28-Abbotts-HUMIRA-adalimumab-Receives-U-S-FDA-Approval-for-the-Treatment-of-Adult-Patients-with-Moderate-to-Severe-Ulcerative-Colitis | archive-date=19 November 2019 | url-status=live | access-date=18 November 2019}}</ref>

=== 판상건선 ===
중등도에서 중증의 만성 [[판상건선]]이 몸의 여러 부위에 존재하는 성인을 아달리무맙으로 치료할 수 있다고 밝혀져 있다.<ref>{{저널 인용| vauthors = Croom KF, McCormack PL | title = Adalimumab | journal = Am J Clin Dermatol | volume = 10 | issue = 1 | pages = 43–50 | year = 2009 | pmid = 19170412 | doi = 10.2165/0128071-200910010-00008 }}</ref> 중등도에서 중증의 건선이 있을 때 지속적인 투여와 간헐적인 투여 모두 효과적인 치료가 된다.<ref>{{저널 인용|vauthors=Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, Strober BE, Kaul M, Gu Y, Okun M, Papp K | display-authors=6 |title=Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial |journal=J. Am. Acad. Dermatol. |volume=58 |issue=1 |pages=106–15 |date=January 2008 |pmid=17936411 |doi=10.1016/j.jaad.2007.09.010 }}</ref>

=== 화농성 한선염 ===
[[화농성 한선염]]은 피부가 접히는 부위인 엉덩이와 겨드랑이 등에 반복적으로 염증이 생겨 [[종기]]나 염증성 결절이 생기는 병이다. 아달리무맙은 2015년에 화농성 한선염 치료제로 승인을 받았다.<ref name="hidradenitis suppurativa" /><ref>{{저널 인용|vauthors=Gulliver W, Zouboulis CC, Prens E, Jemec GB, Tzellos T |title=Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa |journal=Rev Endocr Metab Disord |volume=17 |issue=3 |pages=343–351 |date=September 2016 |pmid=26831295 |pmc=5156664 |doi=10.1007/s11154-016-9328-5 }}</ref><ref>{{저널 인용|vauthors=Maarouf M, Clark AK, Lee DE, Shi VY |title=Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials |journal=J Dermatolog Treat |volume=29 |issue=5 |pages=441–449 |date=August 2018 |pmid=29098911 |doi=10.1080/09546634.2017.1395806 |s2cid=39246564 }}</ref>

=== 소아 특발성 관절염 ===
4세 이상의 소아에서 발생한 중등도에서 중증의 소아 특발성 관절염에 대해 아달리무맙이 증상을 줄일 수 있다고 밝혀져 있다.<ref>{{저널 인용|vauthors=Brunner HI, Nanda K, Toth M, Foeldvari I, Bohnsack J, Milojevic D, Rabinovich CE, Kingsbury DJ, Marzan K, Chalom E, Horneff G, Kuester RM, Dare JA, Trachana M, Jung LK, Olson J, Minden K, Quartier P, Bereswill M, Kalabic J, Kupper H, Lovell DJ, Martini A, Ruperto N | display-authors=6 |title=Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry 7-Year Interim Results |journal=Arthritis Care & Research |volume= 72|issue= 10|pages= 1420–1430|date=August 2019 |pmid=31421019 |doi=10.1002/acr.24044 |pmc=7589221 |doi-access=free }}</ref><ref>{{저널 인용|vauthors=Horneff G, Seyger MM, Arikan D, Kalabic J, Anderson JK, Lazar A, Williams DA, Wang C, Tarzynski-Potempa R, Hyams JS | display-authors=6 |title=Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's Disease |journal=J. Pediatr. |volume=201 |pages=166–175.e3 |date=October 2018 |pmid=30054164 |doi=10.1016/j.jpeds.2018.05.042 |doi-access=free }}</ref><ref>{{저널 인용|vauthors=Correll CK, Bullock DR, Cafferty RM, Vehe RK |title=Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis |journal=Clin. Rheumatol. |volume=37 |issue=2 |pages=549–553 |date=February 2018 |pmid=29103180 |doi=10.1007/s10067-017-3890-4 |s2cid=20099281 }}</ref>

=== 비감염성 포도막염 ===
[[포도막염]]은 눈의 [[포도막]]에 발생한 염증으로, 아달리무맙은 감염으로 인한 경우가 아닌 포도막염의 치료에 사용할 수 있다.<ref name="Humira FDA label" /><ref name="Humira EPAR" />

== 부작용 ==
아달리무맙이 [[결핵]] 등의 중증 감염 위험을 높인다는 강한 수준의 근거가 있으며, 다양한 암의 발생 위험도 증가된다고 보고된 바 있다.<ref>{{저널 인용|vauthors=Hochman D, Wolff B |title=Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis |journal=JAMA |volume=296 |issue=18 |pages=2203; author reply 2203–4 |date=November 2006 |pmid=17090763 |doi=10.1001/jama.296.18.2203-a }}</ref> 그러나 이러한 관련성은 아달리무맙 자체의 문제가 아닌, 아달리무맙으로 치료하는 질환들로 인해 악성 종양 발생 위험이 증가되어 있는 점을 반영하는 것일 수 있다. 2018년의 [[체계적 문헌고찰]] 연구에서는 아달리무맙이나 다른 TNF 억제제로 치료 받은 만성 염증성 질환 환자들에서 그렇지 않은 사람들과 비교했을 때 암의 발생률이 증가하지 않는다고 밝혔다. 단, [[비흑색종 피부암]]은 예외일 수 있다고 보고되었다.<ref name="ChenFriedman2018">{{저널 인용|last1=Chen|first1=Yuehong|last2=Friedman|first2=Marcia|last3=Liu|first3=Gang|last4=Deodhar|first4=Atul|last5=Chu|first5=Cong-Qiu|title=Do tumor necrosis factor inhibitors increase cancer risk in patients with chronic immune-mediated inflammatory disorders?|journal=Cytokine|volume=101|year=2018|pages=78–88|issn=1043-4666|doi=10.1016/j.cyto.2016.09.013|pmid=27688201|s2cid=20837188| name-list-style = vanc}}</ref>

심각한 [[간]] 손상, [[탈수초]] [[중추신경계]] 질환, [[심부전]]이 드물게 보고되기도 하였다. FDA에서는 의사들에게 잠재적인 환자를 보다 신중히 선별하고 모니터링하도록 [[블랙박스 경고문]]을 남겼으며, 이 경고문은 아달리무맙과 다른 TNF 억제제의 라벨에 등재되었다.<ref name=medguide>{{웹 인용| title = Humira Medication Guide | url = http://www.rxabbott.com/pdf/humira_medguide.pdf | date = October 2018 | access-date = 9 September 2019 | archive-date = 13 November 2008 | archive-url = https://web.archive.org/web/20081113194837/http://www.rxabbott.com/pdf/humira_medguide.pdf | url-status = live }}</ref> [[아나필락시스]]나 다른 심각한 알레르기 반응도 발생 가능성이 있다.<ref name=medguide />

== 각주 ==
{{각주}}

== 외부 링크 ==
* {{보고서 인용| title=AusPAR: Adalimumab | website=[[Therapeutic Goods Administration]] (TGA) | date=September 2020 | url=https://www.tga.gov.au/auspar/auspar-adalimumab-1 }}
* {{웹 인용| url = https://druginfo.nlm.nih.gov/drugportal/name/adalimumab | publisher = US National Library of Medicine| work = Drug Information Portal| title = Adalimumab }}

[[분류:단클론 항체]]
[[분류:TNF 억제제]]
[[분류:면역 억제제]]
[[분류:항류마티스제]]
[[분류:세계 보건 기구 필수 의약품]]